Wake Forest University School of Medicine
Epidemiology and Prevention
Michelle M. Mielke, Ph.D. is Chair of the Department of Epidemiology and Prevention, Professor of Epidemiology, and Professor of Gerontology and Geriatric Medicine at Wake Forest University School of Medicine. Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative diseases. One focus of her research is understanding the utility of blood-based biomarkers for implementation at the population-level for screening and diagnosing Alzheimer’s disease and related dementias. Another focus of Dr. Mielke’s research is on understanding sex and gender differences in the development and progression of Alzheimer’s disease and related dementias. Dr. Mielke is PI of several NIH-funded clinical- and epidemiological-based grants and has published over 420 manuscripts. She received the John R. Raymond Mentor Award from the Women Scholars Initiative and recently became a Fellow in the American Association for the Advancement of Science (AAAS), Section on Neuroscience.

Moderator of 1 Session

Session Time
08:40 - 10:40
Session Type
SYMPOSIUM
Date
Fri, 08.03.2024
Room
Auditorium VIII

Presenter of 2 Presentations

RACIAL DISCRIMINATION DURING MIDDLE AGE PREDICTS HIGHER SERUM PHOSPHORYLATED TAU AND NEUROFILAMENT LIGHT CHAIN LEVELS A DECADE LATER

Session Type
SYMPOSIUM
Date
Fri, 08.03.2024
Session Time
08:40 - 10:40
Room
Auditorium VIII
Lecture Time
08:40 - 08:55

Abstract

Aims

Black Americans have a greater risk of developing dementia compared to White Americans. Exposure to racial discrimination and high levels of perceived stress and trauma are associated with cognitive decline. However, the underlying biological mechanisms by which stress and discrimination contribute to cognitive decline are not understood. We assessed whether cumulative exposure to racial discrimination during middle age predicted change in Alzheimer’s disease and neurodegeneration-related blood biomarkers over an 11-year period.

Methods

We used psychosocial and demographic data from 255 Black Americans enrolled in the Family and Community Health Study (FACHS). Participants completed the Schedule of Racist Events at three visits between 2002 and 2008. In 2008 and 2019, serum was obtained. Measures of phosphorylated tau 181 (P-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were assayed on the Quanterix simoa HD-X analyzer. We hypothesized that discrimination assessed during middle age would predict increases in these serum biomarkers as the participants aged into their 60s.

Results

In 2008, participants were a mean (standard deviation, SD) age of 46 (6.3) years; 19.3% had an education level below 12 years; and 45.3% had income below 150% of the federal poverty level. Higher reported discrimination between 2002 and 2008 was not associated with serum biomarkers in 2008. However, higher levels of reported discrimination was associated with a greater increase in levels of both P-tau181 (b=0.183, p=0.003) and NfL (b=1.42, p=0.014) between 2008 and 2019 in models adjusting for age, education, BMI, and gender. Discrimination was not associated with subsequent levels of GFAP.

Conclusions

These findings suggest that early racial discrimination is associated with increased AD pathology and neurodegeneration later in life among Black Americans.

Hide

SEX-BASED DIFFERENCES AND APPLICATIONS OF BLOOD BASED BIOMARKERS TO LARGE POPULATIONS

Session Type
PRE CONFERENCE SYMPOSIUM
Date
Tue, 05.03.2024
Session Time
08:00 - 15:30
Room
Auditorium VI+VII
Lecture Time
12:55 - 13:15